)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
OPKO Health
OPKO Health (OPK) investor relations material
OPKO Health Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 continuing-operations revenue rose 16% YoY to $65.4M; operating loss narrowed to $31.4M, while continuing-operations net loss was $35.5M.
Nine-month revenue increased 30% to $206.5M and operating loss narrowed to $81.4M; net loss was $116.8M versus $194.4M, with prior-year results affected by note-exchange charges.
Pending Labcorp sale of substantially all remaining diagnostic operations would refocus continuing operations on Global Products and Innovative Biotech.
Financial highlights
Q3 product revenue was $41.8M (+11% YoY); licensing, collaboration and other revenue was $23.6M (+26%); total continuing-operations revenue was $65.4M (+16%).
Q3 consolidated operating loss was $31.4M versus $33.6M; net loss was $53.5M versus net income of $21.6M, including $18.0M of discontinued-operations loss.
Nine-month product revenue rose 8% to $122.8M, licensing and collaboration revenue increased 82% to $83.7M, and total revenue reached $206.5M.
Nine-month discontinued operations generated $218.5M revenue and a $25.6M net loss; Q3 revenue was $71.8M.
Cash, cash equivalents and restricted cash were $403.2M at quarter-end; nine-month operating cash use was $99.1M.
Outlook and guidance
FY 2026 continuing-operations revenue guidance is $268M–$278M, including products of $164M–$169M and IP and other revenue of $105M–$110M; costs and expenses are $390M–$395M, including R&D of $125M–$130M.
Q4 continuing-operations revenue is expected at $62M–$72M, including product revenue of $41M–$46M and licensing, collaboration and other revenue of $21M–$27M; Pfizer gross profit share guidance is $12.5M–$15M and BARDA funding $3M–$5M.
Full-year consolidated revenue and total-cost guidance was withdrawn due to the pending Labcorp transaction; guidance continues for retained operations.
Sale-related costs are expected to total ~$125M from Q4 2026 through the transition-services period; Q4 discontinued-operations loss is forecast at ~$40M, or ~$0.05/share.
An FDA IND application for the LA-PTH program with Entera is expected in late 2026; BARDA remaining performance-obligation revenue of $33.5M is expected through February 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OPKO Health
- Transitioning to a therapeutics-focused model with unique multi-specific assets and strong partnerships.OPK
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose, losses narrowed, and cash reserves strengthened amid pipeline and partnership gains.OPKQ2 2026
- All proposals passed; clinical pipeline and cash flow strong; $98M buyback authorization remains.OPKAGM 2026
- Multiple clinical milestones expected in 2024-2025, including key data from MDX-2001 and Merck EBV vaccine.OPKJefferies Global Healthcare Conference 2026
- Approval of the 2026 Equity Incentive Plan is sought to maintain equity-based compensation.OPKProxy filing
- Advancing a broad clinical pipeline and global partnerships, supported by strong financials.OPKCorporate presentation
- Q4 revenue dropped post-divestiture, but R&D and pharma growth support a strong 2026 outlook.OPKQ4 2025
- Q3 2025 saw a major asset sale, higher operating income, and strong cash reserves.OPKQ3 2025
- Q1 2025 saw lower losses, strong cash, asset sales, and a $225M oncology deal with LabCorp.OPKQ1 2025
Next OPKO Health earnings date
Q4 202626 Feb, 2027
OPKO Health
Next OPKO Health earnings date
Q4 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
OPKO Health, Inc., together with its subsidiaries, provides diagnostic and pharmaceutical products to patients in the United States and internationally. The company offers clinical laboratory diagnostic services under the Diagnostic Systems Laboratories (DSL) brand name. It also develops and commercializes pharmaceutical products for oncology, cardiovascular disease, hospital intensive care, gout and metabolic disorders, reproductive health and urology; as well as complementary dietary supplement products for women’s health, eye care and mineral deficiencies. In addition, it engages in the research and development of proprietary medical imaging contrast agents for use in cardiac electrophysiological procedures; along with advanced personalized genetic diagnostics technology using microfluidics extracted from blood samples to help identify genetic markers associated with disease onset or progression; as well as biomarkers associated with efficacy that are useful in assessing treatment options